Health
6.5
FDA mandates GLP-1 labels warn of rare blindness risk NAION
Published 5 h ago3 sourcesEvidence: Reported
SeverityModerateBBC WorldUS
HealthReportedMedium
4.8
Harvard study links Novo's Ozempic to increased risk of vision loss
A Harvard University study has found an association between Novo Nordisk's Ozempic and an elevated risk of vision loss, prompting calls for updated safety warnings. The finding is based on observational data and causality is not yet established. This could affect regulatory scrutiny and prescribing practices for GLP-1 medications.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Score Breakdown
Mosaic Score4.8
Model confidence0.5
Significance0.5
Source credibility0.2
Intelligence Tags
Locations
Boston
Entities
United Statescountry
Related signals
8 foundHealth
5.6
FDA Adds Eye Risk Warning to GLP-1 Labels After Review of 126 Trials
Published 10 h ago2 sourcesEvidence: Reported
SeverityModerateEl EspectadorLow-rated sourceUS
Health
4.9
FDA warns GLP-1 drugs Ozempic, Mounjaro may raise risk of serious eye condition
Published 17 h ago1 sourceEvidence: Reported
SeverityModeratePoder360Low-rated sourceUS
Health
4.8
Novo's Wegovy shows improved liver values in post hoc analysis of Essence trial
Published 1 d ago1 sourceEvidence: Reported
SeverityModerateDagens IndustriLow-rated sourceDK
Health
4.7
FDA flags rare eye-stroke risk in GLP-1 drugs
Published 1 d ago1 sourceEvidence: Reported
SeverityModerateSTAT NewsLow-rated sourceUS
Health
5.8
FDA mandates vision-loss warning on weight-loss pens after rare eye disease signal
Published 6 h ago3 sourcesEvidence: Reported
SeverityModerateAssessedDeveloping storyInfoMoneyUS
Health
5.4
GLP-1 weight-loss boom risks diverting pharma focus from insulin supply, warns foundation
Published 10 h ago2 sourcesEvidence: Reported
SeverityModerateGuardian WorldLow-rated sourceNL
Health
5.2
FDA Approves Novel Stroke Drug; Warns GLP-1s May Raise Eye Condition Risk
Published 9 h ago3 sourcesEvidence: Reported
SeverityModerateAssessedDeveloping storySTAT NewsLow-rated sourceUS